BLASZYK MICHAEL D
Known title: DirectorCIK: 0001371407
BLASZYK MICHAEL D's purchase track record
BLASZYK MICHAEL D has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 6/5/2023 | IBRX | $198K | -47.7% | +33.3% | +6.9% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| IBRX | ▲ Buy | Open Market | 23,430 | $64K | 6/5/2023 | View on chart |
| IBRX | ▲ Buy | Open Market | 48,000 | $133K | 6/5/2023 | View on chart |
| IBRX | ▲ Buy | Open Market | 485 | $1K | 6/5/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 7, 2026
IBRX Posts Best Week In 7 Months On Trump Cancer Panel News
ImmunityBio shares recorded their strongest week in over seven months, driven by reports that a member of Trump's cancer panel supports the company's Anktiva drug. This positive news coincided with the stock breaking through key resistance levels. While the recent surge has lifted the price significantly, the stock remains within its 52-week range of $1.95 to $12.43.
IBRX Posts Best Week In 7 Months On Trump Cancer Panel News. ImmunityBio shares recorded their strongest week in over seven months, driven by reports that a member of Trump's cancer panel supports the company's Anktiva drug. This positive news coincided with the stock breaking through key resistance levels. While the recent surge has lifted the price significantly, the stock remains within its 52-week range of $1.95 to $12.43.